Clinical study of Tanreqing Capsules in the treatment of community-acquired pneumonia in adult

Efficacy and safety evaluation of Tanreqing Capsules in the treatment of community-acquired pneumonia (phlegm-heat obstructing lung syndrome) in adult: A randomized, double-blind, placebo-controlled, single-c

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005920

Enrollment

Unknown

Registered

2022-04-27

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired pneumonia

Interventions

Control Group:Placebo + CAP standard treatment

Experiment Group:TRQC + CAP standard treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All the following criteria must be conformed before inclusion: ?Inpatient aged from 18 to 80; ?Conforming diagnosis criteria of non-severe CAP; ?Conforming TCM diagnosis criteria of wind-warmth and lung-heat disease, phlegm-heat obstructing lung syndrome; ?Patients with clear consciousness, articulateness and adequate understanding of the trail process; ?Volunteer to participate in clinical trial with favorable compliance and signed informed consent.

Exclusion criteria

Exclusion criteria: Conforming to any term of the following criteria must be excluded: ?Patients with severe CAP ?Women who are pregnant or breastfeeding ?Patients with TRQC-relative allergic history or ADR history ?Patients with lung cancer, pulmonary tuberculosis, pulmonary atelectasis or pulmonary edema, etc.; ?Patients with psychiatric disorder or severe primary diseases of the cardio-cerebrovascular, liver, kidney or hematopoietic system; ?Patients with chronic alcohol or drug abuse; ?Patients who are participating in other clinical trials or have participated in other clinical trials within 1 month; ?Patients with viral, mycoplasma or chlamydia infection suggested by pathogenetic examination.

Design outcomes

Primary

Measure	Time frame
Lesion elimination score of pneumonia X-ray image;Time to normal body temperature;	—

Secondary

Measure	Time frame
Stool routine test;TCM syndrome score;Coagulation Factor Test;Neutrophils (Percentange);Overall efficacy;Interleukin 6 (IL-6) level;C-reactive protein (CRP) level;Interferon gamma (IFN-?) level;White blood cell count;Procalcitonin (PCT) level;Urinalysis;Neutrophil count;Liver function test;kidney function test;	—

Countries

China

Contacts

Public ContactLiu Jianbo

13538759071@163.com+86 13538759071

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026